Literature DB >> 31017465

Optimisation and usefulness of quantitative analysis of 18F-florbetapir PET.

Daniel Fakhry-Darian1,2, Neva Hiten Patel1,2, Sairah Khan2, Tara Barwick2, William Svensson2, Sameer Khan2, Richard J Perry3, Paresh Malhotra3,4, Christopher J Carswell3,4, Kuldip S Nijran1,2, Zarni Win2.   

Abstract

OBJECTIVES: This study investigates the usefulness of quantitative SUVR thresholds on sub types of typical (type A) and atypical (non-type A) positive (Aβ+) and negative (Aβ-) 18F-florbetapir scans and aims to optimise the thresholds.
METHODS: Clinical 18F-florbetapir scans (n = 100) were categorised by sub type and visual reads were performed independently by three trained readers. Inter-reader agreement and reader-to-reference agreement were measured. Optimal SUVR thresholds were derived by ROC analysis and were compared with thresholds derived from a healthy control group and values from published literature.
RESULTS: Sub type division of 18F-florbetapir PET scans improves accuracy and agreement of visual reads for type A: accuracy 90%, 96% and 70% and agreement κ > 0.7, κ ≥ 0.85 and -0.1 < κ < 0.9 for all data, type A and non-type A respectively. Sub type division also improves quantitative classification accuracy of type A: optimum mcSUVR thresholds were found to be 1.32, 1.18 and 1.48 with accuracy 86%, 92% and 76% for all data, type A and non-type A respectively.
CONCLUSIONS: Aβ+/Aβ- mcSUVR threshold of 1.18 is suitable for classification of type A studies (sensitivity = 97%, specificity = 88%). Region-wise SUVR thresholds may improve classification accuracy in non-type A studies. Amyloid PET scans should be divided by sub type before quantification. ADVANCES IN KNOWLEDGE: We have derived and validated mcSUVR thresholds for Aβ+/Aβ- 18F-florbetapir studies. This work demonstrates that division into sub types improves reader accuracy and agreement and quantification accuracy in scans with typical presentation and highlights the atypical presentations not suited to global SUVR quantification.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31017465      PMCID: PMC6732916          DOI: 10.1259/bjr.20181020

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  17 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

Authors:  Adam S Fleisher; Kewei Chen; Xiaofen Liu; Auttawut Roontiva; Pradeep Thiyyagura; Napatkamon Ayutyanont; Abhinay D Joshi; Christopher M Clark; Mark A Mintun; Michael J Pontecorvo; P Murali Doraiswamy; Keith A Johnson; Daniel M Skovronsky; Eric M Reiman
Journal:  Arch Neurol       Date:  2011-07-11

3.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

4.  Use of florbetapir-PET for imaging beta-amyloid pathology.

Authors:  Christopher M Clark; Julie A Schneider; Barry J Bedell; Thomas G Beach; Warren B Bilker; Mark A Mintun; Michael J Pontecorvo; Franz Hefti; Alan P Carpenter; Matthew L Flitter; Michael J Krautkramer; Hank F Kung; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Eric P Reiman; P Eric M Reiman; Simone P Zehntner; Daniel M Skovronsky
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272

5.  Quantification of 18F-florbetapir PET: comparison of two analysis methods.

Authors:  Chloe Hutton; Jerome Declerck; Mark A Mintun; Michael J Pontecorvo; Michael D Devous; Abhinay D Joshi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-05       Impact factor: 9.236

6.  Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation.

Authors:  A P Nayate; J G Dubroff; J E Schmitt; I Nasrallah; R Kishore; D Mankoff; D A Pryma
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-12       Impact factor: 3.825

7.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

Authors:  Susan M Landau; Ming Lu; Abhinay D Joshi; Michael Pontecorvo; Mark A Mintun; John Q Trojanowski; Leslie M Shaw; William J Jagust
Journal:  Ann Neurol       Date:  2013-12       Impact factor: 10.422

8.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

Authors:  Christopher M Clark; Michael J Pontecorvo; Thomas G Beach; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Anupa Arora; Alan P Carpenter; Matthew L Flitter; Abhinay D Joshi; Michael J Krautkramer; Ming Lu; Mark A Mintun; Daniel M Skovronsky
Journal:  Lancet Neurol       Date:  2012-06-28       Impact factor: 44.182

9.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline.

Authors:  Susan M Landau; Mark A Mintun; Abhinay D Joshi; Robert A Koeppe; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

10.  Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Authors:  V Camus; P Payoux; L Barré; B Desgranges; T Voisin; C Tauber; R La Joie; M Tafani; C Hommet; G Chételat; K Mondon; V de La Sayette; J P Cottier; E Beaufils; M J Ribeiro; V Gissot; E Vierron; J Vercouillie; B Vellas; F Eustache; D Guilloteau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-18       Impact factor: 9.236

View more
  10 in total

1.  Advances in neurodegenerative and psychiatric imaging: introductory editorial.

Authors:  Amy L Kotsenas; Meike W Vernooij; John D Port
Journal:  Br J Radiol       Date:  2019-09       Impact factor: 3.039

2.  Using radiomics-based modelling to predict individual progression from mild cognitive impairment to Alzheimer's disease.

Authors:  Jiehui Jiang; Min Wang; Ian Alberts; Xiaoming Sun; Taoran Li; Axel Rominger; Chuantao Zuo; Ying Han; Kuangyu Shi; For The Alzheimer's Disease Neuroimaging Initiative
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-15       Impact factor: 10.057

3.  Grey zone amyloid burden affects memory function: the SCIENCe project.

Authors:  J L Ebenau; S C J Verfaillie; K A van den Bosch; T Timmers; L M P Wesselman; M van Leeuwenstijn; H Tuncel; S V S Golla; M M Yaqub; A D Windhorst; N D Prins; F Barkhof; P Scheltens; W M van der Flier; B N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-04       Impact factor: 9.236

4.  Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population.

Authors:  Qiu-Yue Dong; Tao-Ran Li; Xue-Yan Jiang; Xiao-Ni Wang; Ying Han; Jie-Hui Jiang
Journal:  Alzheimers Res Ther       Date:  2021-04-07       Impact factor: 6.982

5.  Radiomics Analysis of Magnetic Resonance Imaging Facilitates the Identification of Preclinical Alzheimer's Disease: An Exploratory Study.

Authors:  Tao-Ran Li; Yue Wu; Juan-Juan Jiang; Hua Lin; Chun-Lei Han; Jie-Hui Jiang; Ying Han
Journal:  Front Cell Dev Biol       Date:  2020-12-03

6.  A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images.

Authors:  Marco Bucci; Irina Savitcheva; Gill Farrar; Gemma Salvadó; Lyduine Collij; Vincent Doré; Juan Domingo Gispert; Roger Gunn; Bernard Hanseeuw; Oskar Hansson; Mahnaz Shekari; Renaud Lhommel; José Luis Molinuevo; Christopher Rowe; Cyrille Sur; Alex Whittington; Christopher Buckley; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-12       Impact factor: 9.236

7.  Image-guided selection of Gd@C-dots as sensitizers to improve radiotherapy of non-small cell lung cancer.

Authors:  Xiaofen Ma; Chaebin Lee; Tao Zhang; Jinghua Cai; Hui Wang; Fangchao Jiang; Zhanhong Wu; Jin Xie; Guihua Jiang; Zibo Li
Journal:  J Nanobiotechnology       Date:  2021-09-22       Impact factor: 10.435

8.  β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.

Authors:  Tao-Ran Li; Yun-Xia Yao; Xue-Yan Jiang; Qiu-Yue Dong; Xian-Feng Yu; Ting Wang; Yan-Ning Cai; Ying Han
Journal:  Alzheimers Res Ther       Date:  2022-05-12       Impact factor: 8.823

9.  Using Deep Learning Radiomics to Distinguish Cognitively Normal Adults at Risk of Alzheimer's Disease From Normal Control: An Exploratory Study Based on Structural MRI.

Authors:  Jiehui Jiang; Jieming Zhang; Zhuoyuan Li; Lanlan Li; Bingcang Huang
Journal:  Front Med (Lausanne)       Date:  2022-04-21

10.  Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease.

Authors:  Etsuko Imabayashi; Naoyuki Tamamura; Yuzuho Yamaguchi; Yuto Kamitaka; Muneyuki Sakata; Kenji Ishii
Journal:  Ann Nucl Med       Date:  2022-07-11       Impact factor: 2.258

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.